Bavarian Nordic
| Company type | Public |
|---|---|
| |
| ISIN | DK0015998017 |
| Industry | Biotechnology |
| Founded | 1994 |
| Headquarters | , Denmark |
Key people | |
| Products | Imvanex, Imvamune, Jynneos, Rabipur/RabAvert, Encepur, Vivotif, Vaxchora, Mvabea, Vimkunya |
| Revenue | 7.062 billion kr. (2023) |
| Total assets | 14.373 billion kr. (2023) |
| Total equity | 10.340 billion kr. (2023) |
Number of employees | 1.379 (2023) |
| Website | bavarian-nordic |
| Footnotes / references | |
Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.